文献速递血栓与止血

改良凝血波形分析用于测量抗因子IXa/因子X双特异性抗体艾米珠单抗存在下的血浆凝血潜能

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
PubMed 文献 · J Thromb Haemost · 2018-05-13

本研究开发了基于凝血酶原时间(PT)/活化部分凝血活酶时间(APTT)混合触发试剂的改良凝血波形分析参数Ad|min1|,用于量化艾米珠单抗(Emi)在血友病A血浆中的整体凝血潜能。结果显示Ad|min1|与Emi浓度呈浓度依赖性升高,且与因子VIII或旁路制剂共存在时活性互不掩盖。该检测可能有助于评估Emi治疗血友病A患者的凝血潜能。

要点

  • PT/APTT混合触发试剂(1:15:135)下Ad|min1|与Emi浓度对应,每1 μg/mL Emi约相当于0.2-0.4 IU/dL因子VIII。
  • Emi加入伴或不伴抑制物的血友病A血浆后,Ad|min1|呈浓度依赖性升高,存在个体差异。
  • 因子VIII或旁路制剂与Emi共存时Ad|min1|呈剂量依赖性升高,活性互不掩盖。

核心结论

  • PT/APTT试剂触发的改良凝血波形分析可评估Emi治疗血友病A患者的整体凝血潜能,增强的活性既不被因子VIII或旁路制剂掩盖,也不掩盖它们。

研究设计与样本

  • 体外研究:采用PT/APTT混合试剂进行凝血波形分析,开发改良参数Ad|min1|,在血友病A血浆中评估Emi的凝血潜能。

主要发现

  • 混合触发试剂(PT/APTT/缓冲液,1:15:135)下Ad|min1|与Emi浓度对应,每1 μg/mL Emi约相当于0.2-0.4 IU/dL因子VIII。
  • Emi加入伴或不伴抑制物的血友病A血浆后,Ad|min1|呈浓度依赖性升高,存在个体差异。
  • 不同浓度因子VIII加入含Emi的血友病A血浆后,Ad|min1|呈剂量依赖性升高。
  • 活化凝血酶原复合物与Emi混合加入血友病A血浆后,Ad|min1|呈剂量依赖性升高。
  • 重组活化因子VII实验中,凝血时间比Ad|min1|更好地反映增强的凝血潜能。

临床怎么用

  • 作者认为PT/APTT试剂触发的改良凝血波形分析可能为评估Emi治疗血友病A患者的整体凝血潜能提供有用手段。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials The activated partial prothrombin time (aPTT) cannot predict the activity of emicizumab (Emi). Adjusted clot waveform analyses using a prothrombin time (PT)/aPTT initiator were developed. Activity of Emi in the co-presence of factor VIII or bypassing agents was quantified. This assay is useful for assessing coagulation potential in Emi-treated hemophilia A. SUMMARY: Background Emicizumab is an anti-activated factor IX/FX bispecific antibody that mimics activated FVIII cofactor function. Emicizumab does not require activation by thrombin, and its effect on shortening the activated partial thromboplastin time (APTT) is much greater than that of FVIII. Therefore, the APTT has limited utility in hemophilia A (HA) patients treated with emicizumab. Aim To evaluate the global coagulation potential of emicizumab. Methods Clot waveform analysis (CWA) with prothrombin time (PT)/APTT mixed reagents was used to define hemostatic monitoring protocols in HA patients. A modified parameter, adjusted-|min1| (Ad|min1|), was developed. Maximum and minimum percentage transmittance were defined as 100% and 0% in the precoagulation and postcoagulation phases, respectively. Ad|min1| was calculated as an index of the maximum velocity of the coagulation process. Results Ad|min1| obtained with mixed-trigger reagent (PT/APTT/buffer, 1 : 15 : 135) in the presence of emicizumab optimally corresponded to the conversion rate estimated in animals; 0.2-0.4 IU dL-1 equivalent FVIII per 1 μg mL-1 emicizumab). Ex vivo addition of emicizumab to HA plasma with or without inhibitors resulted in concentration-dependent increases in Ad|min1|, with some individual variations. The addition of various concentrations of FVIII to HA plasma mixed with emicizumab resulted in dose-dependent increases in Ad|min1|. Similarly, mixtures of activated prothrombin complex concentrate and emicizumab added to HA plasma resulted in dose-dependent increases in Ad|min1|. In contrast, enhanced coagulation potential appeared to be better defined by the clot time than by Ad|min1| in experiments using recombinant activated FVII. Conclusion The PT/APTT reagent-triggered adjusted CWA could provide a useful means of assessing global coagulation potential in emicizumab-treated HA patients, with enhanced activity neither masking nor being masked by FVIII or bypassing agents.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Nogami K, Matsumoto T, Tabuchi Y, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. J Thromb Haemost. 2018. PMID: 29645406. doi:10.1111/jth.14022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。